|Mr. Corey N. Conn||Chief Financial Officer and Director||156.86k||N/A||55|
|Mr. Adel Abdullah||VP of Operations||N/A||N/A||N/A|
|Mrs. Sandra K. Sweet||Director of Sales and Marketing||N/A||N/A||N/A|
|Mr. Aaron Hargrave||Clinical Applications Specialist||N/A||N/A||N/A|
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers PET molecular imaging systems, clinical and support services, automated radiopharmaceutical systems, and radiopharmaceuticals and radioisotope processing and production. The companys Attrius system based on cardiac PET technology enables healthcare providers to more accurately diagnose heart disease, improve patient outcomes, and practice cost effective medicine. It is also focused on increasing Sr-82 supply through the processing of proton irradiated target material from domestic and foreign suppliers; and recycling Sr-82 from spent generators. Positron Corporation was founded in 1983 and is based in Westmont, Illinois. On, September 7, 2016, Positron Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. On August 28, 2015, an involuntary petition for reorganization under Chapter 11 was filed against Positron Corporation.
Positron Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.